Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

This trial tests a new drug called INX-315 (a CDK2 inhibitor) in people with certain advanced cancers. CDK2 is a protein that drives cell division in some tumours, and blocking it may slow or stop cancer growth. The study focuses on three cancer types: hormone receptor-positive breast cancer (after CDK4/6 inhibitor treatment), ovarian cancer with a CCNE-1 gene amplification, and other solid tumours with CCNE-1 amplification. **You may be eligible if...** - You have advanced breast cancer (ER+/HER2-) that progressed after CDK4/6 inhibitor therapy, OR - You have platinum-resistant ovarian cancer with CCNE-1 amplification, OR - You have another advanced solid tumour with confirmed CCNE-1 amplification that has progressed on standard treatment - You are in good overall health (ECOG 0 or 1) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have previously received a CDK2 or CDK2/4/6 inhibitor - You have active brain metastases causing symptoms or requiring steroids - You have lung disease (interstitial lung disease, radiation pneumonitis) - You have a prolonged QT interval on your ECG or history of QT prolongation - You have HIV, active hepatitis, or uncontrolled infection - You are pregnant or breastfeeding - You have difficulty swallowing oral medications Talk to your doctor to see if this trial is right for you.